HIM
KYNB

Hillsdale Investment Management’s Kyntra Bio KYNB Stock Holding History

Hillsdale Investment Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,352
Closed -$631K – 591
2023
Q1 		$631K Buy
+1,352
New +$715K 0.05% 263

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hillsdale Investment Management's KYNB Position: Q2 2023 in Review

Hillsdale Investment Management sold out of Kyntra Bio (KYNB) in Q2 2023, closing a stake of 1,352 shares — an estimated $631K sold.

Hillsdale Investment Management first reported a position in KYNB in Q1 2023 and held it in 1 quarter. The position peaked at $631K in Q1 2023. 152 funds tracked by Wall St. Rank hold KYNB as of Q2 2023.

  • Hillsdale Investment Management reported no remaining Kyntra Bio position as of Q2 2023 after selling out during the quarter.
  • Hillsdale Investment Management sold 1,352 Kyntra Bio shares in Q2 2023, an estimated $631K.
  • Hillsdale Investment Management first reported a position in Kyntra Bio in Q1 2023 and held it in 1 quarter.
  • Hillsdale Investment Management's Kyntra Bio position peaked at $631K in Q1 2023.
  • 152 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2023.

Based on Hillsdale Investment Management's 13F filing for Q2 2023, filed 11 Aug 2023.